Literature DB >> 11593073

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia.

D C Goff1, L Leahy, I Berman, T Posever, L Herz, A C Leon, S A Johnson, G Lynch.   

Abstract

CX516, a positive modulator of the glutamatergic alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor, improves performance in tasks requiring learning and memory in animals. CX516 was added to clozapine in 4-week, placebo-controlled, dose-finding (N = 6) and fixed-dose (N = 13) trials. CX516 was tolerated well and was associated with moderate to large, between-group effect sizes compared with placebo, representing improvement in measures of attention and memory. These preliminary results suggest that CX516 and other "ampakines" hold promise for the treatment of schizophrenia.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11593073     DOI： 10.1097/00004714-200110000-00005

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


  53 in total

1.  Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Authors:  Surendra P Singh; Vidhi Singh
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

Review 2.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

Review 3.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 4.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 5.  Challenges for and current status of research into positive modulators of AMPA receptors.

Authors:  Simon E Ward; Benjamin D Bax; Mark Harries
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

Review 6.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

Review 7.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

8.  Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.

Authors:  Kent Jardemark; Monica M Marcus; Anna Malmerfelt; Mohammed Shahid; Torgny H Svensson
Journal:  Psychopharmacology (Berl)       Date:  2011-11-09       Impact factor: 4.530

Review 9.  Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders.

Authors:  Stefano Marenco; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

10.  Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat.

Authors:  M L Woolley; K A Waters; J E Gartlon; L P Lacroix; C Jennings; F Shaughnessy; A Ong; D J Pemberton; M H Harries; E Southam; D N C Jones; L A Dawson
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.